EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

JAK inhibition decreases the autoimmune burden in Down syndrome

Angela L Rachubinski, Elizabeth Wallace, Emily Gurnee, Belinda A Enriquez-Estrada, Kayleigh R Worek, Keith P Smith, Paula Araya, Katherine A Waugh, Ross E Granrath, Eleanor Britton, Hannah R Lyford, Micah G Donovan und 10 weitere

eLife · 2024

DOI: 10.7554/elife.99323 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift eLife, 2024. Verfasst von Angela L Rachubinski und 21 weiteren Autor:innen. Beteiligte Einrichtung: Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, United States. Hauptthemen laut MEDLINE: Down Syndrome, Janus Kinase Inhibitors, Piperidines, Pyrimidines. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIAMS NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Individuals with Down syndrome (DS), the genetic condition caused by trisomy 21 (T21), display clear signs of immune dysregulation, including high rates of autoimmunity and severe complications from infections. Although it is well established that T21 causes increased interferon responses and JAK/STAT signaling, elevated autoantibodies, global immune remodeling, and hypercytokinemia, the interplay between these processes, the clinical manifestations of DS, and potential therapeutic interventions remain ill defined.

Methods

We report a comprehensive analysis of immune dysregulation at the clinical, cellular, and molecular level in hundreds of individuals with DS, including autoantibody profiling, cytokine analysis, and deep immune mapping. We also report the interim analysis of a Phase II clinical trial investigating the safety and efficacy of the JAK inhibitor tofacitinib through multiple clinical and molecular endpoints.

Results

We demonstrate multi-organ autoimmunity of pediatric onset concurrent with unexpected autoantibody-phenotype associations in DS. Importantly, constitutive immune remodeling and hypercytokinemia occur from an early age prior to autoimmune diagnoses or autoantibody production. Analysis of the first 10 participants to complete 16 weeks of tofacitinib treatment shows a good safety profile and no serious adverse events. Treatment reduced skin pathology in alopecia areata, psoriasis, and atopic dermatitis, while decreasing interferon scores, cytokine scores, and levels of pathogenic autoantibodies without overt immune suppression.

Conclusions

JAK inhibition is a valid strategy to treat autoimmune conditions in DS. Additional research is needed to define the effects of JAK inhibition on the broader developmental and clinical hallmarks of DS. Funding: NIAMS, Global Down Syndrome Foundation. Clinical trial number: NCT04246372 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Down SyndromeJanus Kinase InhibitorsPiperidinesPyrimidinesAdolescentAdultChildChild, PreschoolFemaleHumansInfantMaleYoung AdultAutoantibodiesAutoimmunityCytokinesPyrrolesMiddle Aged

Stichwörter der Autor:innen

JAKautoimmunitydown syndromehumanimmunologyinflammationinterferonsmedicineskin

Substanzen

AutoantibodiesCytokinesJanus Kinase InhibitorsPiperidinesPyrimidinesPyrrolestofacitinib

Autor:innen und Institutionen

  • Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, United States.
  • Department of Pediatrics, Section of Developmental Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, United States.
  • Department of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, United States.
  • Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, United States.
  • Department of Internal Medicine, University of Colorado Anschutz Medical Campus, Aurora, United States.
  • Department of Pediatrics, Section of Developmental Biology, University of Colorado Anschutz Medical Campus, Aurora, United States.

ORCID-Profile: Kelly D Sullivan, Matthew D Galbraith, Joaquín M Espinosa

Förderung

  • NIAID NIH HHS
  • NIAMS NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • NCI NIH HHS
  • NCATS NIH HHS
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • National Cancer Institute
  • National Center for Advancing Translational Sciences

Zitieren

APA

Rachubinski, A. L., Wallace, E., Gurnee, E., Enriquez-Estrada, B. A., Worek, K. R., Smith, K. P., Araya, P., Waugh, K. A., Granrath, R. E., Britton, E., Lyford, H. R., Donovan, M. G., Eduthan, N. P., Hill, A. A., Martin, B., Sullivan, K. D., Patel, L., Fidler, D. J., Galbraith, M. D., …, & Espinosa, J. M. (2024). JAK inhibition decreases the autoimmune burden in Down syndrome. eLife. https://doi.org/10.7554/elife.99323

Vancouver

Rachubinski AL, Wallace E, Gurnee E, Enriquez-Estrada BA, Worek KR, Smith KP, et al. JAK inhibition decreases the autoimmune burden in Down syndrome. eLife. 2024. doi:10.7554/elife.99323

BibTeX
@article{Rachubinski2024,
  author = {Rachubinski, Angela L and Wallace, Elizabeth and Gurnee, Emily and Enriquez-Estrada, Belinda A and Worek, Kayleigh R and Smith, Keith P and Araya, Paula and Waugh, Katherine A and Granrath, Ross E and Britton, Eleanor and Lyford, Hannah R and Donovan, Micah G and Eduthan, Neetha Paul and Hill, Amanda A and Martin, Barry and Sullivan, Kelly D and Patel, Lina and Fidler, Deborah J and Galbraith, Matthew D and Dunnick, Cory A and Norris, David A and Espinosa, Joaquín M},
  title = {JAK inhibition decreases the autoimmune burden in Down syndrome},
  journal = {eLife},
  year = {2024},
  doi = {10.7554/elife.99323}
}
Kostenlos starten →